Group 1 - The company has approved a share repurchase plan using its own or raised funds, with a maximum repurchase price of RMB 20.83 per share and a total repurchase amount between RMB 100 million and RMB 200 million, valid for 12 months from April 15, 2025, to April 14, 2026 [1] - As of July 31, 2025, the company has repurchased a total of 11,412,800 shares, representing 1.19% of the total share capital, with a total expenditure of RMB 163,769,877, excluding transaction fees [1] - The highest and lowest prices for the repurchased shares were RMB 15.30 and RMB 13.31 per share, respectively [1] Group 2 - The company will adhere to relevant regulations and make repurchase decisions based on market conditions, ensuring timely information disclosure regarding the progress of the share repurchase [2]
浙江医药股份有限公司 关于股份回购进展公告